Form 13-F position report

BIOGEN INC

Reported by Sarissa Capital Management LP

BIIB CUSIP 09062X103 Manager CIK 0001577524

Reported 950 shares, unchanged from the prior quarter.

Reported value 4.5%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.14% This manager · Q3 2026
Shares 950 Quarter-end amount reported
Reported value $214,586 Fair value at quarter end
Consecutive quarters held 2 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 154269000
2022-03-31 135416000
2022-06-30 131133000
2022-09-30 171681000
2022-12-31 178059560
2023-03-31 178773290
2023-06-30 183158550
2023-09-30 165257430
2023-12-31 166389110
2024-03-31 138650090
2024-06-30 149060260
2024-09-30 5223988
2024-12-31 0
2026-06-30 205257
2026-09-30 214586

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for BIOGEN INC held by Sarissa Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 950 0 (0.0%) 0.14% $214,586 2026-11-16
Q2 2026 New 950 +950 (0.0%) 0.12% $205,257 2026-08-14
Q4 2024 Reduced 0 -26,950 (-100.0%) 0 $0 2025-02-14
Q3 2024 Reduced 26,950 -616,050 (-95.8%) 1.3% $5,223,988 2024-11-14
Q2 2024 Unchanged 643,000 0 (0.0%) 25.16% $149,060,260 2024-08-14
Q1 2024 Unchanged 643,000 0 (0.0%) 24.26% $138,650,090 2024-05-15
Q4 2023 Unchanged 643,000 0 (0.0%) 25.64% $166,389,110 2024-02-14
Q3 2023 Unchanged 643,000 0 (0.0%) 22.26% $165,257,430 2023-11-14
Q2 2023 Unchanged 643,000 0 (0.0%) 18.23% $183,158,550 2023-08-14
Q1 2023 Unchanged 643,000 0 (0.0%) 22.86% $178,773,290 2023-05-15
Q4 2022 Unchanged 643,000 0 (0.0%) 21.19% $178,059,560 2023-02-14
Q3 2022 Unchanged 643,000 0 (0.0%) 19.4% $171,681,000 2022-11-14
Q2 2022 Unchanged 643,000 0 (0.0%) 13.2% $131,133,000 2022-08-15
Q1 2022 Unchanged 643,000 0 (0.0%) 12.8% $135,416,000 2022-05-16
Q4 2021 Unchanged 643,000 0 (0.0%) 13.35% $154,269,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1128 managers reported BIOGEN INC for Q3 2026.

Managers reporting BIOGEN INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Reduced 16,780,911 -1,436,328 0.16% $3,790,472,025 54 qtrs
BlackRock Inc Added 16,089,189 +103,453 0.05% $3,634,226,091 9 qtrs
PRIMECAP MANAGEMENT CO CA Added 15,197,022 +42,416 2.13% $3,432,703,328 54 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 9,670,881 +19,764 0.05% $2,184,458,600 3 qtrs
STATE STREET CORPORATION Added 7,562,205 +217,878 0.05% $1,708,150,865 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 6,572,163 -32,773 0.07% $1,484,520,178 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 4,507,404 +58,109 0.05% $1,014,558,357 54 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 3,458,781 +341,312 0.14% $781,269,452 54 qtrs
MORGAN STANLEY Added 2,506,411 +95,140 0.03% $566,148,674 54 qtrs
JPMorgan Chase & Co Added 2,039,161 +216,021 0.03% $463,032,706 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
950
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.